These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36288657)

  • 1. Design, synthesis, and biological evaluation of 2-arylamino-4-(piperidin-4-yloxy)pyrimidines as potent EGFR
    Tian L; Li X; Lv Z; Yang Y; Wang L; Xu D; Ma X; Xu Y
    Bioorg Med Chem; 2022 Nov; 74():117052. PubMed ID: 36288657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noncovalent EGFR T790M/L858R inhibitors based on diphenylpyrimidine scaffold: Design, synthesis, and bioactivity evaluation for the treatment of NSCLC.
    Chen L; Zhang Y; Tian L; Wang C; Deng T; Zheng X; Wang T; Li Z; Tang Z; Meng Q; Sun H; Li L; Ma X; Xu Y
    Eur J Med Chem; 2021 Nov; 223():113626. PubMed ID: 34218082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors.
    Ding S; Gao Z; Hu Z; Qi R; Zheng X; Dong X; Zhang M; Shen J; Long T; Zhu Y; Tian L; Song W; Liu R; Li Y; Sun J; Duan W; Liu J; Chen Y
    Eur J Med Chem; 2022 Aug; 238():114492. PubMed ID: 35696862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR).
    Fawwaz M; Mishiro K; Nishii R; Sawazaki I; Shiba K; Kinuya S; Ogawa K
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32599930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of pyrido[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine derivatives as novel EGFR
    Fu J; Yu J; Zhang X; Chang Y; Fan H; Dong M; Li M; Liu Y; Hu J
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2205605. PubMed ID: 37106478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of hydroxamic acid-substituted 2,4-diaryl aminopyrimidines as potent EGFRT790M/L858R inhibitors for the treatment of NSCLC.
    Chen L; Zhang Y; Wang C; Tang Z; Meng Q; Sun H; Qi Y; Ma X; Li L; Li Y; Xu Y
    Bioorg Chem; 2021 Sep; 114():105045. PubMed ID: 34161879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of highly potent and selective EGFR
    Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
    Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel 4-arylamino-quinazoline derivatives as EGFR
    Gan W; Wang C; Pan Q; Li Y; Guo Y; Fan D; Peng Y; Rao Z; Xu S; Zheng P; Zhu W
    Bioorg Chem; 2022 Oct; 127():105994. PubMed ID: 35792314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
    Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
    Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
    Chen L; Chi F; Wang T; Wang N; Li W; Liu K; Shu X; Ma X; Xu Y
    Bioorg Med Chem; 2018 Dec; 26(23-24):6087-6095. PubMed ID: 30471829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
    Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
    Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
    Pawara R; Ahmad I; Nayak D; Wagh S; Wadkar A; Ansari A; Belamkar S; Surana S; Nath Kundu C; Patil C; Patel H
    Bioorg Chem; 2021 Oct; 115():105234. PubMed ID: 34399322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells.
    Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2016 Aug; 34(4):407-15. PubMed ID: 27044261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational design and synthesis of 2,4-dichloro-6-methyl pyrimidine derivatives as potential selective EGFR
    Duan L; Chu C; Huang X; Yao H; Wen J; Chen R; Wang C; Tu Y; Lv Q; Pan Q; Xu S
    Arch Pharm (Weinheim); 2024 May; 357(5):e2300736. PubMed ID: 38381049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
    Xiao Q; Qu R; Gao D; Yan Q; Tong L; Zhang W; Ding J; Xie H; Li Y
    Bioorg Med Chem; 2016 Jun; 24(12):2673-80. PubMed ID: 27131639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation.
    Zuo Y; Long Z; Li R; Le Y; Zhang S; He H; Yan L
    Eur J Med Chem; 2024 Feb; 265():116106. PubMed ID: 38169271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
    Li J; An B; Song X; Zhang Q; Chen C; Wei S; Fan R; Li X; Zou Y
    Eur J Med Chem; 2021 Feb; 212():113019. PubMed ID: 33429247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR
    Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y
    Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis and Biological Evaluation of the Quinazoline Derivatives as L858R/T790M/C797S Triple Mutant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Zhang M; Wang Y; Wang J; Liu Z; Shi J; Li M; Zhu Y; Wang S
    Chem Pharm Bull (Tokyo); 2020; 68(10):971-980. PubMed ID: 32999149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of highly potent and selective CRBN-recruiting EGFR
    Zhang W; Li P; Sun S; Jia C; Yang N; Zhuang X; Zheng Z; Li S
    Eur J Med Chem; 2022 Aug; 238():114509. PubMed ID: 35691176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.